Trial Profile
A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (greater than or equal to 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 29 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jun 2011 Planned end date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.